Pancreatic Cancer Panel
Use
This test is aimed at individuals who either present relevant features or have a clinical or suspected diagnosis of familial pancreatic cancer. It is also intended for individuals who currently have or have had pancreatic cancer, as well as those with first-degree relatives diagnosed with the disease. Additionally, individuals of Ashkenazi Jewish ancestry with a personal or family history of pancreatic cancer may find this test relevant.
Special Instructions
The test employs NGS with CNV analysis on the PGselect platform.
Limitations
The analysis will not detect all potential genetic changes; regions with insufficient coverage or with problematic sequences may not be fully analyzed, affecting the detection of some mutations. The panel focuses on 18 genes relevant to pancreatic cancer but does not rule out the presence of variants in genes not included in the panel. The test has not been cleared or approved by the FDA.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
2-3 weeks
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided